Region Vaermland

Running trials

• Not yet recruiting

  Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

  2026-525324-26-00· Phase 2· Source

• Recruiting

  The HIt HArd and hiT Early in Multiple Sclerosis Trial

  NCT07517185· Phase 2· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.

  2024-511182-10-01· Phase 4· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Recruiting

  Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)

  2023-506998-35-00· Phase 3· Source

• Recruiting

  Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

  NCT06488482· Phase 3· Source

• Recruiting

  Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX)

  2023-508398-10-00· Phase 4· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Source

• Recruiting

  SACK

  2022-501600-10-00· Phase 3· Source

• Active, not recruiting

  Ixekizumab Diabetes Intervention Trial (I-DIT)

  NCT04589325· Phase 2· Source

• Recruiting

  Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

  NCT04910802· Phase 4· Source

• Active, not recruiting

  NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

  NCT04335669· Phase 3· Source

• Recruiting

  ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  NCT03903835· Phase 3· Source

• Recruiting

  Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

  NCT02901184· Phase 3· Source

• Active, not recruiting

  Adjuvant Low Dose Aspirin in Colorectal Cancer

  NCT02647099· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• High blood pressure2 recruiting
• ANCA-associated vasculitis1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Prostate cancer1 recruiting
• Schizophrenia1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults

  NCT05622201· Phase 2· Source

• Completed

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· Phase 4· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source